Literature DB >> 32146483

Impact of Lymphovascular Invasion on Survival Outcome in Patients With Gastric Cancer.

Di Mei1,2, Bochao Zhao1, Jiale Zhang1, Rui Luo1, Huiwen Lu1, Huimian Xu1, Baojun Huang1.   

Abstract

OBJECTIVES: To evaluate the prognostic significance of lymphovascular invasion (LVI) for patients with gastric cancer (GC).
METHODS: A total of 1,720 consecutive patients who underwent curative gastrectomy were retrospectively identified. The association between LVI and clinicopathologic characteristics was determined and its impact on survival outcome was evaluated.
RESULTS: LVI was detected in 21.3% of GC patients, 5.9% of patients with early GC, 24.0% of patients with advanced GC, and 6.7% of node-negative patients using H&E staining. Tumor size (odds ratio [OR], 1.509; 95% confidence interval [CI], 1.159-1.965; P < .01), differentiated type (OR, 1.817; 95% CI, 1.377-2.398; P < .001), and the depth of tumor invasion (OR, 3.011; 95% CI, 2.174-4.171; P < .001) were independent predictive factors for LVI. LVI-positive patients have a poorer prognosis than LVI-negative patients, irrespective of tumor stage or lymph node metastasis. LVI was an independent prognostic factor for patients with GC (hazard ratio, 1.299; 95% CI, 1.112-1.518; P < .001).
CONCLUSIONS: LVI provided additional prognostic information for GC patients, and LVI-positive patients should be considered candidates for adjuvant chemotherapy. © American Society for Clinical Pathology, 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Gastric cancer; Lymphovascular invasion (LVI); Prognostic; Survival

Year:  2020        PMID: 32146483     DOI: 10.1093/ajcp/aqaa021

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Meta-analysis of the relationship between lymphovascular invasion and prognosis of patients with stage I gastric cancer.

Authors:  Dailong Li; Wanqiang Li; Yaqi Pang; Siqi Liu; Lu Xu; Xinhua Xu
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

2.  Can lymphovascular invasion be predicted by contrast-enhanced CT imaging features in patients with esophageal squamous cell carcinoma? A preliminary retrospective study.

Authors:  Yang Li; Haiyan Su; Li Yang; Meng Yue; Mingbo Wang; Xiaolong Gu; Lijuan Dai; Xiangming Wang; Xiaohua Su; Andu Zhang; Jialiang Ren; Gaofeng Shi
Journal:  BMC Med Imaging       Date:  2022-05-17       Impact factor: 2.795

3.  Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma.

Authors:  Shen Gao; Xuan Li; Weigang Shi; Limin Huo; Huimin Liu
Journal:  J Oncol       Date:  2022-03-30       Impact factor: 4.375

4.  Lymph but Not Blood Vessel Invasion Is Independent Prognostic in Lung Cancer Patients Treated by VATS-Lobectomy and Might Represent a Future Upstaging Factor for Early Stages.

Authors:  Melanie Biesinger; Nele Eicken; Alexander Varga; Michael Weber; Milos Brndiar; Georg Erd; Peter Errhalt; Klaus Hackner; Sarah Hintermair; Alexander Petter-Puchner; Axel Scheed; Elisabeth Stubenberger; Bahil Ghanim
Journal:  Cancers (Basel)       Date:  2022-04-08       Impact factor: 6.575

5.  The Value of the C-Reactive Protein-to-Lymphocyte Ratio for Predicting Lymphovascular Invasion Based on Nutritional Status in Gastric Cancer.

Authors:  Rui Xu; Shuomeng Xiao; Zhi Ding; Ping Zhao
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

6.  Clinicopathological factors associated with the presence of tumor deposits in resected gastric cancer patients.

Authors:  Oscar Paredes Torres; Sofia Prado Cucho; Luis Taxa Rojas; Carlos Luque-Vasquez; Ivan Chavez; Eduardo Payet Meza; Eloy Ruiz Figueroa; Francisco Berrospi Espinoza
Journal:  Heliyon       Date:  2021-05-29

7.  Contrast-Enhanced CT-Based Radiomics Analysis in Predicting Lymphovascular Invasion in Esophageal Squamous Cell Carcinoma.

Authors:  Yang Li; Meng Yu; Guangda Wang; Li Yang; Chongfei Ma; Mingbo Wang; Meng Yue; Mengdi Cong; Jialiang Ren; Gaofeng Shi
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.